Table 1 Clinical features of study population at baseline and over the 4 months observation period

 Age, years, mean (SD)

56 (12)

 Male, n (%)

107 (89%)

 New Zealand European ethnicity, n (%)

74 (62%)

 New Zealand Māori ethnicity, n (%)

20 (17%)

 Pacific ethnicity, n (%)

16 (13%)

 Asian ethnicity, n (%)

10 (8%)

 Duration of gout, years, mean (SD)

15 (12)

 No. of self-reported flares in preceding 4 months, mean (SD)

4.5 (6.0)

 Allopurinol use, n (%)

64 (53%)

 Colchicine use, n (%)

32 (27%)

 Prednisone use, n (%)

16 (13%)

 NSAID use, n (%)

60 (50%)

 Presence of tophi, n (%)

43 (36%)

 Serum urate, mmol/L, mean (SD)

0.42 (0.10)

 Days to first self-reported flare, mean (SD)

13.1 (27.6)

 Number of self-reported flares, mean (SD)

2.1 (2.0)

 Number of months with ≥1 self-reported flare, mean (SD)

2.4 (1.3)

 Days with self-reported flare, mean (SD)

21.1 (18.3)

 Days to first Gaffo-CART defined, mean (SD)

41.3 (47.3)

 Number of Gaffo-CART defined flares, mean (SD)

0.9 (1.0)

 Number of months with ≥1 Gaffo-CART defined flare, mean (SD)

1.7 (1.3)

 Days with Gaffo-CART defined flare, mean (SD)

7.9 (9.3)

 Average pain score (range 0–10), mean (SD) ^a

0.77 (1.74)

 Average swollen joint count (/66), mean (SD)^b

0.66 (1.57)

 Average tender joint count (/68), mean (SD) ^b

0.67 (1.24)

 Average C-reactive protein, mg/L, mean (SD) ^b

4.59 (7.47

 Average physician global assessment (range 0–5), mean (SD) ^b

1.46 (1.23)

 Average patient global assessment (range 0–5), mean (SD) ^b

1.46 (1.24)